Trial of Two Schedules of Perifosine for Patients With Solid Tumors or Lymphomas
Status:
Completed
Trial end date:
2011-09-01
Target enrollment:
Participant gender:
Summary
This is a study of the drug perifosine for patients who have no standard treatment options.
This study is designed to identify which cancer types respond to perifosine, and determine
which regimen of perifosine is most effective in each one. Patients with either solid tumors
or with lymphomas for whom this protocol represents reasonable or optimal treatment will be
randomized to receive either perifosine 100 mg daily or 900 mg weekly until disease
progression. Based on currently available data it is anticipated that these doses should be
easily tolerated by most patients.